Lacey Clawson
Foot & Ankle Surgery · Abilene, TXNPI 1497986202
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Arthrex accounts for 66.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $9,687 and has fallen 88.5% since, to $1,112 in 2025.
Across 99 payments — averaging $118.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$8K
- Pylant Medical$2K
- Stryker$238
- Bioventus LLC$169
- Zimmer Biomet$143
- Vertex$137
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$6,00051%
- Travel & lodging$1,58613%
- Food & beverage$2,98725%
- Education$1,20010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 16 | $7,828 |
| Pylant Medical | 15 | $2,161 |
| Stryker | 7 | $238 |
| Bioventus LLC | 5 | $169 |
| Zimmer Biomet | 2 | $143 |
| Vertex | 6 | $137 |
| Ferring Pharmaceuticals Inc. | 10 | $133 |
| Johnson & Johnson | 4 | $128 |
| Amgen | 5 | $110 |
| Argentum Medical | 1 | $106 |
| Pacira Pharmaceuticals Incorporated | 5 | $102 |
| Smith+Nephew | 2 | $65 |
| Anika Therapeutics, Inc. | 2 | $49 |
| Hydrocision, Inc. | 1 | $45 |
| Abbott | 2 | $36 |
| Integra Lifesciences Corporation | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| AbbVie | 1 | $30 |
| Innovation Technologies Inc | 1 | $24 |
| Globus Medical | 1 | $23 |
| Molnlycke Health Care US, LLC | 1 | $23 |
| Treace Medical Concepts, Inc. | 1 | $22 |
| Mimedx Group, Inc. | 1 | $21 |
| Curonix LLC | 1 | $20 |
| Davol Inc. | 1 | $19 |
| Organogenesis Inc. | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Orthofix Medical, Inc. | 1 | $14 |
| Advanced Oxygen Therapy Inc. | 1 | $8 |
How this compares
$11,773 in reported general payments places this provider in the 75th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 257 | $4,019 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 129 | $1,273 |
| Pregabalin | 66 | $1,198 |
| Allopurinol | 80 | $1,193 |
| Terbinafine Hcl | 35 | $811 |
| Doxycycline Hyclate | 65 | $518 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 17 | $308 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 24 | $300 |
| Tramadol Hcl | 111 | $260 |
| Nystatin | 23 | $256 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 40 | $186 |
| Celecoxib | 22 | $163 |
| Meloxicam | 21 | $49 |
| Colchicine | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Abilene
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
- Abdul NurudeenHouston$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.